Biologics Reached Record Share Of Novel Approvals In 2009
Executive Summary
The pharmaceutical industry's strategy of looking to biologics as a source of innovation is clearly demonstrated in FDA's novel approvals in 2009
You may also be interested in...
Follow-on Biologic's Day Will Come - Post 2015, Teva Says
The generic giant acknowledges biogenerics as a major growth driver, but probably not before 2015.
Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers
Centocor Ortho Biotech's Stelara (ustekinumab) brings a novel mechanism and superior efficacy to the plaque psoriasis marketplace, but in terms of risk management, the anti-inflammatory biologic differs little from the tumor necrosis factor inhibitor class
H1N1 Vaccines Get Green Light In U.S., But Is Anything Else Needed?
Here comes the swine flu again, but this time tens of millions of people could be immunized thanks to the first round of vaccines due in mid-October